Geode Capital Management LLC Has $265.75 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Geode Capital Management LLC grew its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 7.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,090,480 shares of the medical research company's stock after purchasing an additional 143,825 shares during the period. Geode Capital Management LLC owned approximately 1.58% of Natera worth $265,747,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of NTRA. M&T Bank Corp raised its position in shares of Natera by 7.9% during the 3rd quarter. M&T Bank Corp now owns 5,513 shares of the medical research company's stock worth $699,000 after buying an additional 405 shares in the last quarter. Gordian Capital Singapore Pte Ltd increased its stake in shares of Natera by 211.5% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 8,193 shares of the medical research company's stock valued at $1,040,000 after acquiring an additional 5,563 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Natera during the third quarter worth approximately $1,267,000. MML Investors Services LLC lifted its position in Natera by 34.6% in the third quarter. MML Investors Services LLC now owns 4,593 shares of the medical research company's stock worth $583,000 after purchasing an additional 1,180 shares during the period. Finally, Orion Portfolio Solutions LLC bought a new position in Natera during the 3rd quarter valued at $929,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on NTRA shares. Craig Hallum boosted their price objective on Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. StockNews.com cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. TD Cowen raised their price objective on shares of Natera from $155.00 to $175.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Piper Sandler boosted their target price on shares of Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a report on Monday, November 18th. Finally, The Goldman Sachs Group raised their target price on shares of Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $152.67.

Natera Stock Performance

Shares of NTRA traded up $0.10 during mid-day trading on Friday, hitting $166.55. The company's stock had a trading volume of 1,211,176 shares, compared to its average volume of 1,330,468. The stock's 50-day moving average is $144.02 and its two-hundred day moving average is $124.66. The firm has a market capitalization of $21.99 billion, a PE ratio of -94.63 and a beta of 1.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a one year low of $57.22 and a one year high of $175.63.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business's quarterly revenue was up 63.9% on a year-over-year basis. During the same period last year, the business posted ($0.95) EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.61 EPS for the current year.

Insider Activity at Natera

In other Natera news, insider Jonathan Sheena sold 2,700 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total transaction of $344,439.00. Following the completion of the transaction, the insider now directly owns 284,741 shares in the company, valued at $36,324,409.37. This represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction on Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the transaction, the chief executive officer now directly owns 195,686 shares of the company's stock, valued at approximately $25,141,737.28. The trade was a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 137,987 shares of company stock worth $21,895,591 over the last three months. Company insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.